axSpA: Moving the needle in time to diagnosis The journey to axial spondyloarthritis (axSpA) diagnosis is often prolonged and challenging. Understanding the factors contributing to the delays is important to improve the clinical, psychological, social and economic outcomes.… https://t.co/wnwtj8jj0q https://t.co/Pds2uxVfJV

Assessment and management of axSpA Dr. Antoni Chan reports on abstract 0818, Defining BASDAI Cut-offs for Disease Activity States in Axial Spondylarthritis – Results from the EuroSpA Collaboration, and abstract 0819, The Assessment of SpondyloArthritis International Society… https://t.co/ropQJdElyb https://t.co/IVn5u2l7iP

#ACR24 BEST Abstracts from Day 1 The RheumNow faculty have parked at the plenaries, trafficked the posters and have been finding the best the meeting offers on the first day. https://t.co/FHu616Jpyq https://t.co/oKuRcGRRAZ

• #ACR 2024 BEST Abstracts from Day 1 | RheumNow

Difficult to Manage Axial Spondyloarthritis Axial spondyloarthritis (axSpA) is a chronic inflammatory disease primarily affecting the spine and sacroiliac joints, causing back pain, stiffness, and reduced mobility. #ACR24 https://t.co/5i5QtJJm16 https://t.co/c4bllA8ngJ

• Difficult to Manage Axial Spondyloarthritis | RheumNow

PREDICT-SpA: Evaluating the influence of gender on disease assessment tools Dr. Sheila Reyes reports on abstract 0571, Gender-specific Performance of Disease Activity Assessment Tools in Axial Spondyloarthritis: Ancillary Analysis of the PREDICT-SpA Study, presented at #ACR24.… https://t.co/EGlCap6pEw

Among axSpA patients enrolled in the BE MOBILE 1&2, those who received Bimekizumab achieved ASAS40 response earlier vs PBO Improvements in spinal pain and physical function were significantly reported as early as wk 1 in those who received BKZ vs PBO @RheumNow #ACR24 abs2363 https://t.co/JmcQdURTY4

• https://x.com/RHEUMarampa/status/1858613336788574630/photo/1
• https://x.com/RHEUMarampa/status/1858613336788574630/photo/1

SEC demonstrated high retention rates after 5 years in pts with PsA and r-axSpA in this real-world study. Reasons for stopping SEC: lack of efficacy pt decision lost to ffup AEs Reassuring data on SECs position in the treatment of PsA/AS. @Rheumnow #ACR24 abs2344 https://t.co/zECEsheQIi

• https://x.com/RHEUMarampa/status/1858580860238217419/photo/1

A#2583 Apremilast for axial inflamm in PsA, assess by CANDEN MRI scoring MOSAIC P4 open label trial Reduction in inflammation seen in vertebral bodies & posteriolateral, not in facet joints No changes in SPARCC SIJ, spine - though low baseline SIJ inflammation @RheumNow #ACR24 https://t.co/3GKEGJbtdc

• https://x.com/ericdeinmd/status/1858581617067127217/photo/1

A systematic review & meta-analysis by Dr. JBCorrea et al show that the ff immune-mediated dses are assocd w/⬆️ ocurrence risk after covid19 infection 👇 Behcets SpA SS SLE PMR Pso RA Sjogrens T1DM Vasculitis IBD Ask prior covid infexn in pts history @RheumNow #ACR24 abs2614 https://t.co/TIEglPrmvL

• https://x.com/RHEUMarampa/status/1858590128110784622/photo/1

A higher number of axSpA pts enrolled in BE MOBILE 1&2 who were treated with BKZ achieved remission accdg to the OSI vs. ASDAS ID (40.5% vs 15.2%) at wk 16 until wk 52. OSI a better measure of remission? @RheumNow #ACR24 abs2362 https://t.co/GCHjXQi9S9

• https://x.com/RHEUMarampa/status/1858595035559932201/photo/1

Sharma @Amansharmapgi et al. DADA2. Clinical manifestations of 101(!) patients. @RheumNow #ACR24 Abstr#2647 https://t.co/Tkk6Rz6rtT https://t.co/frvFPYy4xf

• Clinical Characteristics , Treatment Outcomes and Predictors of Mortality in a …
• https://x.com/RichardPAConway/status/1858603584356774002/photo/1

Reproductive Issues in axSpA: Fertility and Pregnancy axSpA affects young patients with symptom onset occurring in early adulthood. Apart from pain and quality of life, reproductive issues also arise because patients who are diagnosed with the disease are also in their… https://t.co/8tLFOvFqdO https://t.co/E3AOOCHTgu